

8TH International Symposium on Pneumococci and Pneumococcal Diseases

Iguaçu Falls, Brazil
March 11-15, 2012

Session 1

GAPP. Tactics and Tools for a Global Campaign Against Pneumonia.

Organized by

Thomas Cherian (Co-Chair, WHO, Geneva); Kim Mulholland (Co-Chair, Australia); Miguel Treguaghi (Argentina) Shamim Qazi (WHO) Mathuram Santosham (USA) Richard Adegbola (The Gambia) Orin Levine (USA) Carlos Grijalva

Historical overview of the GAPP. From Alice Spring to Iguaçu Falls.

By Kim Mulholland (Australia) 5 minutes

Progress with national planning and country experience with the roll out of GAPP.

By Samira Aboubaker, WHO, (Switzerland) 15 minutes + 5' discussion

The Kenya Action Plan for Prevention and Control of Pneumonia.

By Annah Wamae, Ministry of Health, (Kenya) 15 minutes + 5' discussion

Lessons from COMPAS for measuring impact of future pneumonia interventions.

By Xavier Saez Llorens, (Panamá). 15 minutes + 5' discussion

4 oral abstract presentations: 7 minutes + 3' discussion each

Session 2

Progress and Innovations in etiologic diagnosis of pneumococcal infections and nasopharyngeal colonization.

Organized by

Keith P. Klugman (Co-Chair, USA); Herminia de Lencastre (Co-Chair, Portugal); José Echenique (Argentina)

Introduction

By Keth Klugman (5 Minutes)

Recent improvements in the diagnosis of pneumococcal pneumonia.

By Werner C. Albrich (Switzerland) 15 minutes + 5' discussion

Detection of multiple serotypes in the nasopharynx.

By Catherine Satzke (Australia) 15 minutes + 5' discussion

5 oral abstract presentations. 8 minutes + 5' discussion each

Session 3

Advanced epidemiology of pneumococcal infections and antimicrobial resistance.

Organized by

María Cristina de Brandileone (Co-Chair, Brasil); Raquel Sá-Leão (Co-Chair, Portugal); Ana Lucia Andrade (Brasil); Anne von Gottberg (South Africa); Philip P. Hill (New Zealand); Josefina Liñares (España)

Introduction

By María Cristina Brandileone (2 minutes)

A multi-site analysis of serotype specific changes in invasive pneumococcal disease after conjugate vaccine introduction among children < 5 years old

By Daniel Feikin (USA) 14 minutes + 4' discussion

A multi-site analysis of serotype specific changes in invasive pneumococcal disease after conjugate vaccine introduction among persons ≥ 5 years old

By Matthew Moore (USA) 14 minutes + 4' discussion

The weaker link: challenges in studying the epidemiology of non-invasive pneumococcal disease.

By Ron Dagan, (Israel). 14 minutes + 4' discussion

Molecular epidemiology of pneumococcal diseases in Latin America: the last twenty years.

By Alejandra Corso, (Argentina). 14 minutes + 4' discussion

3 oral abstract presentations. 7 minutes + 3' discussion each

Session 4

7 lessons from pcv7. A tale of four countries

Organized by

Ron Dagan (Co-Chair, Israel); Katherine O'Brien (Co-Chair, USA); María Hortal (Uruguay); Peter McIntyre (Australia); María Luisa Ávila (Costa Rica); Grant MacKenzie (WG); Cynthia Whitney (USA); Elizabeth Miller (UK); Laura Hammit (UK)

Introduction by Katherine O'Brien (USA). 2 minutes

7 Lessons from the first use country. By Cynthia Whitney (USA). 12 minutes

7 lessons from an abbreviated schedule country. By Elizabeth Miller (UK). 12 minutes

7 Lessons from a country without a booster dose. By Peter McIntyre (Australia). 12 minutes

7 lessons from a recently adopting country. By David Greenberg (Israel). 12 minutes

Discussion (speakers remaining on stage). Moderated by Ron Dagan: 15 minutes

4 oral abstract presentations: 8 minutes + 2' discussion each

8TH International Symposium on Pneumococci and Pneumococcal Diseases

Iguaçu Falls, Brazil
March 11-15, 2012

Session 5

Effectiveness of PCV introduction in middle and low-income countries.

Organized by

Shabir Madhi (Co-Chair, South Africa);
Mario Ramirez (Co-Chair, Portugal);
Ángela Gentile (Argentina); Anthony
Scott (USAPERRE); Samba Sow (Mali)

Laboratory-Based Evidence for Vaccine Decision Making and Monitoring. The PAHO-SIREVA experience. By Jean-Marc Gabastou (PAHO, Washington-DC). 15 minutes

Out of Africa: Lessons learnt and Challenges in Evaluating the effectiveness of PCV. By Shabir Madhi (South Africa). 15 minutes

PCVs effectiveness in LATAM, lessons and experience. By Ángela Gentile (Argentina) 15 minutes

Discussion (speakers remaining on stage) Moderated by Mario Ramirez. 15 minutes

4 oral abstract presentations: 8'+3' discussion each

Session 6.

Streptococcus pneumoniae biology and evolution.

Organized by

Alexander Tomasz (Co-Chair, USA);
Stephen Bentley (Co-Chair, UK);
Teresa Camou (Uruguay);

Comparing pneumococcal clone evolution through whole genome analysis. By Stephen Bentley (UK), 15 minutes + 5' discussion.

A genome-wide view of pneumococcal transformation.

By Nicholas Croucher (UK), 15 minutes + 5' discussion

5 oral abstract presentations: 10 minutes + 3' discussion each

Session 7.

Who gets pneumococcal disease and why

Organized by

Allan Cripps (Co-Chair, Australia);
Jeffrey Weiser (Co-Chair, USA); Raul
Ruvinsky (Argentina); Daniel
Stamboulian (Argentina); Eitan
Berezin (Brazil); Ingileif Jónsdóttir
(Iceland)

Host-Microbial interactions: the key to pneumococcal disease.

By Debbie Bogaert (The Netherlands) 15 minutes + 5' discussion

Pneumococcal infection in the elderly.

By Carlos Orihuela (USA) 15 minutes + 5' discussion

5 oral abstract presentations: 10 minutes + 3' discussion each

Session 8.

Immunology of Pneumococcal infections and vaccines.

Organized by

David Goldblatt (Co-Chair, UK); Ger
Rijkers (Co-Chair, The Netherlands)

Introduction by Ger Rijkers, 5 minutes

The immunology of colonization.

By Stephen Gordon (UK) 20 minutes

Comparisons of the immunology of polysaccharide and conjugate vaccines in humans.

By David Goldblatt (UK) 20 minutes

Remainder of session for oral presentations

Session 9.

Novel pneumococcal vaccines and their regulatory pathways.

Organized by

Mark Alderson (Co-Chair, PATH, USA)
Elaine Tuomanen (Co-Chair, USA);
Luciana C. Leite (Brazil)

Clinical and regulatory issues with the development of novel pneumococcal vaccines.

By George Siber (USA) 15 minutes

Immunology and protective mechanisms of pneumococcal protein vaccines.

By Richard Malley (USA) 15 minutes

Progress towards development of a protein-based pneumococcal vaccine.

By Dorota Borys (GSK) 15 minutes

Remainder of session for oral presentations